Multivalent Anti-CD40 Antibodies for Selective Dendritic Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD40 agonist antibodies for cancer treatment often result in adverse side effects such as shock syndrome and cytokine release syndrome due to systemic administration, and have limited potency for activating dendritic cells, which are crucial for anti-tumor responses.
Innovation Solution
Development of multivalent antibodies or antigen-binding fragments with high affinity and specificity for CD40, capable of dual cytotoxic effects on tumor cells, including direct apoptosis and immune cell-mediated cytotoxicity, with enhanced potency for activating dendritic cells compared to B cells, and improved binding specificity to minimize systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-CD40 agonist antibodies are administered systemically, then they can activate immune cells, but they cause adverse side effects such as shock syndrome and cytokine release syndrome
Solution Approach 1:
The patent develops antibody variants with modified binding specificity that preferentially activate dendritic cells over B cells, creating a localized effect on the desired immune cell population while minimizing systemic activation of other cells. This selective activation reduces cytokine release syndrome and shock syndrome while maintaining anti-tumor efficacy
Solution Approach 2:
The invention modifies the binding parameters of anti-CD40 antibodies by altering CDR sequences to achieve differential binding affinity - higher affinity for CD40 on dendritic cells and lower affinity for CD40 on B cells. This parameter optimization enables selective dendritic cell activation at lower doses, reducing systemic toxicity
2Reliability
If anti-CD40 antibodies are used to activate B cells, then humoral immunity is enhanced, but the potency for activating dendritic cells is limited
Solution Approach 1:
The patent creates antibody variants with differentiated binding characteristics that provide strong activation of dendritic cells (primary function) while maintaining adequate B cell activation (secondary function). The local quality of binding - preferential interaction with dendritic cell CD40 - enhances anti-tumor immunity without completely abolishing humoral responses
3Power
If high doses of anti-CD40 antibodies are administered to overcome limited dendritic cell activation, then dendritic cell activation improves, but systemic toxicity increases
Solution Approach 1:
The invention optimizes the binding affinity parameters of the antibody variants to achieve high dendritic cell activation potency at low concentrations. By modifying CDR sequences, the antibodies exhibit enhanced specific binding to dendritic cell CD40, enabling effective activation at doses that avoid systemic toxicity
Solution Approach 2:
The patent employs antibody variants that provide excessive or enhanced activation of dendritic cells through their modified binding properties, achieving the desired immune response at lower doses. This partial focus on dendritic cells rather than all CD40-expressing cells allows for more efficient activation without the need for high systemic doses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies exhibit improved activation of dendritic cells, potentially leading to enhanced anti-tumor immune responses with reduced systemic adverse effects by targeting CD40 with high specificity and potency, thereby increasing the effectiveness of cancer immunotherapy.
Implementation Method 1
an antibody or an antigen-binding fragment thereof with multivalent binding specificity for CD40
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1x10-10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.